Browse
Submit Data
Databases
API
Help

Dataset Information

3 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.

ABSTRACT: Interventions: Subcutaneous injection of cancer peptide vaccines (five peptides) Primary outcome(s): Safety Responsiveness (tumor size) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620388 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Cancer specific vaccine therapy using HLA-A24 restricted epitope-peptide for patients with advanced metastatic colorectal cancer.PhaseI/II clinical trial.

Project description:Interventions: Subctaneus injection of cancer peptide vaccine(three peptides) Primary outcome(s): Safety Overall survival Study Design: Single arm Non-randomized

| 2620437 | ecrin-mdr-crc

Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.

Project description:Interventions: Subcutaneous injection of cancer vaccine (seven peptides) Primary outcome(s): Safty Immunological response (in vitro CTL induction) Study Design: Single arm Non-randomized

| 2620402 | ecrin-mdr-crc

Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.

| 2621744 | ecrin-mdr-crc

A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent colorectal cancers

Project description:Interventions: 1st and 2nd duration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every two weeks, repeated 4 times 3rdduration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every four weeks, repeated 4 times Primary outcome(s): Tumor response: Disease control rate (DCR), best over- all response assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) after Survivin helper peptide vaccine Study Design: Single arm Non-randomized

| 2622923 | ecrin-mdr-crc

Personalized neoantigen peptide vaccine for advanced solid cancer

Project description:Interventions: Personalized neoantigen peptide vaccine consists of 15-30 long peptides combined into four distinct immunizing peptide pools with 0.3 mg of each peptide admixed with 0.5 mg poly-ICLC per pool in a volume of 1 ml.;Experimental Biological/Vaccine;Personalized Neoantigen Peptide vaccine Primary outcome(s): Overall response rate at week 9, 18 on treatment period and every 12 weeks until disease progression or up to 12 months modified RECIST 1.1

| 2568253 | ecrin-mdr-crc

Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.

Project description:Interventions: Subcutaneous injection of cancer vaccine (seven peptides) UFT+LV Primary outcome(s): Safty Immunological response (in vitro CTL induction) Study Design: Single arm Non-randomized

| 2623214 | ecrin-mdr-crc

ClariomS Array to determine the effect of a vaspin-derived peptide on gene expression in fully differentiated primary subcutaneous mouse adipocytes

Project description:Screening for potential target proteases of vaspin revealed rapid and specific cleavage within the vaspin N-terminus, releasing short peptides with cell penetrating activity. For microarray analysis to determine the effect of a vaspin-derived peptide on gene expression in adipocytes, fully differentiated primary mouse adipocytes from subcutaneous AT were treated with 100 nM of peptide for 24 h before harvesting, RNA isolation and microarray analysis. Solvent (water) treated cells served as controls.

2021-03-31 | E-MTAB-9592 | biostudies-arrayexpress

WT1 Trio Peptide-vaccine for Rare Cancers

Project description:Interventions: A patient is vaccinated with Montanide ISA51-adjuvanted WT1 Trio cancer vaccine consisting of two WT1 CTL peptides (WT1-126 and WT1-235) and one WT1 HTL peptide (WT1-332) (2mg each) seven times at the interval of two weeks. Primary outcome(s): Induction of WT1-specific immune responses assessed by WT1-related tests such as WT1-DTH skin reaction and serum levels of WT1 peptide IgG autoantibody at 1M, 2M, and 3M of WT1 Trio vaccine. Study Design: Single arm Non-randomized

| 2638832 | ecrin-mdr-crc

In situ synthesis of peptide microarrays - shadow mask design [3]

Project description:In this paper several computer programs were used to simulate in situ synthesis of peptides using shadow masks and BOC synthesis. The peptides were designed to be random, or pseudo-random, but fulfill requirements of immunosignaturing. This file contains data from actual 330,000 peptide arrays that used the first iteration of the peptide generation algorithm. Monoclonal antibodies were bound to the microarrays and the total number of peptides that distinguished each monoclonal was measured. This provides a baseline against which to compare purely random sequences. One replicate of each peptide was printed on 1 330k peptide microarray. One microarray were tested for each sample. Image was qualified using in-house metrics for quality assurance.

2014-01-16 | E-GEOD-50571 | biostudies-arrayexpress

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

Project description:This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

| 2166328 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data